Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of PASS and GAPP scoring systems

51Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

Abstract

Purpose: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP) are scoring systems to predict metastatic potential in pheochromocytomas (PCC) and paragangliomas (PGLs).The goal of this study is to assess PASS and GAPP as metastatic predictors and to correlate with survival outcomes. Methods: The cohort included PCC/PGL with ≥5 years of follow-up or known metastases. Surgical pathology slides were rereviewed. PASS and GAPP scores were assigned. Univariable and multivariable logistic regression, Kaplan–Meier survival analysis, and Cox proportional hazards were performed to assess recurrence-free survival (RFS) and disease-specific survival (DSS). Results: From 143 subjects, 106 tumors were PCC and 37 were PGL. Metastases developed in 24%. The median PASS score was 6.5 (interquartile range [IQR]: 4.0-8.0) and median GAPP score was 3.0 (IQR: 2.0-4.0). Interrater reliability was low–moderate for PASS (intraclass correlation coefficient [ICC]: 0.6082) and good for GAPP (ICC 0.7921). Older age (OR: 0.969, P = .0170) was associated with longer RFS. SDHB germline pathogenic variant (OR: 8.205, P = .0049), extra-adrenal tumor (OR: 6.357, P

Cite

CITATION STYLE

APA

Wachtel, H., Hutchens, T., Baraban, E., Schwartz, L. E., Montone, K., Baloch, Z., … Fishbein, L. (2020). Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of PASS and GAPP scoring systems. Journal of Clinical Endocrinology and Metabolism, 105(12). https://doi.org/10.1210/clinem/dgaa608

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free